The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe?
Chia‐Chi Wang, Jia‐Horng Kao – 31 January 2019
A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma–Initial, Maximum, Last Classification
Philip Vutien, Jennifer Dodge, Kiran M. Bambha, Eric M. Nordstrom, Jane Gralla, Kristen Campbell, Claire Levek, Trevor Nydam, Oren Fix, George Ioannou, Scott W. Biggins – 31 January 2019 – Risk of recurrent hepatocellular carcinoma (rHCC) after liver transplantation (LT) depends on the pre‐LT HCC burden, tumor behavior, and response to locoregional therapy (LRT). In December 2017, LT priority for HCC was expanded to select patients outside the Milan criteria who respond to LRT.
Prognostic Role of Ammonia in Patients With Cirrhosis
Shalimar, Mohammed Faisal Sheikh, Rajeshwar P. Mookerjee, Banwari Agarwal, Subrat Kumar Acharya, Rajiv Jalan – 31 January 2019 – Ammonia is thought to be central to the pathogenesis of hepatic encephalopathy (HE), but its prognostic role in patients with cirrhosis and acute decompensation is unknown. The aims of this study were to determine the relationship between ammonia levels and severity of HE and its association with organ dysfunction and short‐term mortality. We identified 498 patients from two institutions as part of prospective observational studies in patients with cirrhosis.
Issue Information
31 January 2019
Letter to Editor: The Synergistic Effect of Albumin on Terlipressin in Acute‐on‐Chronic Liver Failure With Acute Kidney Injury
Shengtao Lin, Da Dorothy Zhang, Yuan Gao, Yueke Zhu, Bing Hou – 31 January 2019
Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta‐Analysis
Alessandro Mantovani, Davide Gatti, Giacomo Zoppini, Giuseppe Lippi, Enzo Bonora, Christopher D. Byrne, Valerio Nobili, Giovanni Targher – 31 January 2019 – Recent cross‐sectional studies have examined the association between nonalcoholic fatty liver disease (NAFLD) and bone mineral density (BMD) in children or adolescents, but these have produced conflicting results. We performed a systematic review and meta‐analysis of these published studies to quantify the magnitude of the association, if any, between NAFLD and BMD.
Reply
Vinod Arora, Rakhi Maiwall, Vijayaraghavan Rajan, Ankur Jindal, Saggere Muralikrishna Shasthry, Guresh Kumar, Priyanka Jain, Shiv Kumar Sarin – 31 January 2019
F‐box/WD Repeat‐Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal‐Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice
Lan Bai, Ming‐Ming Chen, Ze‐Dong Chen, Peng Zhang, Song Tian, Yan Zhang, Xue‐Yong Zhu, Ye Liu, Zhi‐Gang She, Yan‐Xiao Ji, Hongliang Li – 31 January 2019 – Inhibition of apoptosis signal‐regulating kinase 1 (ASK1) activation has emerged as a promising target for the treatment of nonalcoholic steatohepatitis (NASH). Multiple forms of posttranslational modifications determine the activity of ASK1. In addition to phosphorylation, recent studies revealed that ubiquitination is essential for ASK1 activation.
Evidence for a Novel Regulatory Interaction Involving Cyclin D1, Lipid Droplets, Lipolysis, and Cell Cycle Progression in Hepatocytes
Heng Wu, Jonathan M. Ploeger, Sushama Kamarajugadda, Douglas G. Mashek, Mara T. Mashek, Juan C. Manivel, Laurie L. Shekels, Jessica L. Lapiro, Jeffrey H. Albrecht – 30 January 2019 – During normal proliferation, hepatocytes accumulate triglycerides (TGs) in lipid droplets (LDs), but the underlying mechanisms and functional significance of this steatosis are unknown. In the current study, we examined the coordinated regulation of cell cycle progression and LD accumulation. As previously shown, hepatocytes develop increased LD content after mitogen stimulation.
A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis–Associated Liver Disease
A. Jay Freeman, Zachary M. Sellers, George Mazariegos, Andrea Kelly, Lisa Saiman, George Mallory, Simon C. Ling, Michael R. Narkewicz, Daniel H. Leung – 29 January 2019 – Approximately 5%‐10% of patients with cystic fibrosis (CF) will develop advanced liver disease with portal hypertension, representing the third leading cause of death among patients with CF. Cystic fibrosis with advanced liver disease and portal hypertension (CFLD) represents the most significant risk to patient mortality, second only to pulmonary or lung transplant complications in patients with CF.